{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:56:30Z","timestamp":1790722590338,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41391-026-01078-8","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T17:19:27Z","timestamp":1770052767000},"page":"678-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fecal incontinence after prostate cancer irradiation: a systematic literature review"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0606-3851","authenticated-orcid":false,"given":"Daniel","family":"Benizri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Duchalais-Dassonneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8177-3245","authenticated-orcid":false,"given":"Jean-Michel","family":"Hannoun-Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"1078_CR1","unstructured":"\u00ab Cancer Today \u00bb https:\/\/gco.iarc.who.int\/today\/ (accessed 1.14.25)."},{"key":"1078_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2214122.","journal-title":"N Engl J Med"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1012348","volume":"365","author":"CU Jones","year":"2011","unstructured":"Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1012348.","journal-title":"N Engl J Med"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"e2015083","DOI":"10.1001\/jamanetworkopen.2020.15083","volume":"3","author":"ZS Zumsteg","year":"2020","unstructured":"Zumsteg ZS, Spratt DE, Daskivich TJ, Tighiouart M, Luu M, Rodgers JP, et al. Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: a secondary analysis of the RTOG 9408 randomized clinical trial. JAMA Netw Open. 2020;3:e2015083 https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.15083.","journal-title":"JAMA Netw Open"},{"key":"1078_CR5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff R-O, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(10)70223-0.","journal-title":"Lancet Oncol"},{"key":"1078_CR6","doi-asserted-by":"publisher","unstructured":"Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, et al. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. J Clin Oncol. 2024;42. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375:1425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1606221.","journal-title":"N Engl J Med"},{"key":"1078_CR8","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary J-P, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018;4:e180039 https:\/\/doi.org\/10.1001\/jamaoncol.2018.0039.","journal-title":"JAMA Oncol"},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/j.ijrobp.2011.02.006","volume":"81","author":"JE Bekelman","year":"2011","unstructured":"Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:e325\u201334. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.006.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","volume":"102","author":"R de Crevoisier","year":"2018","unstructured":"de Crevoisier R, Bayar MA, Pommier P, Muracciole X, P\u00eane F, Dudouet P, et al. Daily versus weekly prostate cancer image-guided radiation therapy: phase 3 multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2018;102:1420\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2006.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ctrv.2018.10.004","volume":"70","author":"DLC Kee","year":"2018","unstructured":"Kee DLC, Gal J, Falk AT, Schiappa R, Chand M-E, Gautier M, et al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials. Cancer Treat Rev. 2018;70:265\u201371. https:\/\/doi.org\/10.1016\/j.ctrv.2018.10.004.","journal-title":"Cancer Treat Rev"},{"key":"1078_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, et al. A Phase III randomized controlled trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391:1413\u201325. https:\/\/doi.org\/10.1056\/nejmoa2403365.","journal-title":"N Engl J Med"},{"key":"1078_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","volume":"26","author":"AU Kishan","year":"2025","unstructured":"Kishan AU, Sun Y, Tree AC, Hall E, Dearnaley D, Catton CN, et al. Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium. Lancet Oncol. 2025;26:459\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(25)00034-8.","journal-title":"Lancet Oncol"},{"key":"1078_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2023.09.004","volume":"22","author":"I Mack","year":"2024","unstructured":"Mack I, Hahn H, G\u00f6del C, Enck P, Bharucha AE. Global prevalence of fecal incontinence in community-dwelling adults: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024;22:712\u2013731.e8. https:\/\/doi.org\/10.1016\/j.cgh.2023.09.004.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.radonc.2010.12.004","volume":"98","author":"Y Maeda","year":"2011","unstructured":"Maeda Y, H\u00f8yer M, Lundby L, Norton C. Faecal incontinence following radiotherapy for prostate cancer: a systematic review. Radiother Oncol. 2011;98:145\u201353. https:\/\/doi.org\/10.1016\/j.radonc.2010.12.004.","journal-title":"Radiother Oncol"},{"key":"1078_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00384-013-1784-8","volume":"29","author":"R Krol","year":"2014","unstructured":"Krol R, Smeenk RJ, van Lin ENJT, Yeoh EEK, Hopman WPM. Systematic review: anal and rectal changes after radiotherapy for prostate cancer. Int J Colorectal Dis. 2014;29:273\u201383. https:\/\/doi.org\/10.1007\/s00384-013-1784-8.","journal-title":"Int J Colorectal Dis"},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ejmp.2016.03.003","volume":"32","author":"V Landoni","year":"2016","unstructured":"Landoni V, Fiorino C, Cozzarini C, Sanguineti G, Valdagni R, Rancati T. Predicting toxicity in radiotherapy for prostate cancer. Phys Med. 2016;32:521\u201332. https:\/\/doi.org\/10.1016\/j.ejmp.2016.03.003.","journal-title":"Phys Med"},{"key":"1078_CR18","unstructured":"Rouvi\u00e8re H, Delmas A. Anatomie humaine: descriptive, topographique et fonctionnelle. Tome 2 11th ed. Paris, France: Masson; 1978."},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/ajg.2014.396","volume":"110","author":"AE Bharucha","year":"2015","unstructured":"Bharucha AE, Dunivan G, Goode PS, Lukacz ES, Markland AD, Matthews CA, et al. Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. Am J Gastroenterol. 2015;110:127\u201336. https:\/\/doi.org\/10.1038\/ajg.2014.396.","journal-title":"Am J Gastroenterol"},{"key":"1078_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijrobp.2010.08.023","volume":"82","author":"RJ Smeenk","year":"2012","unstructured":"Smeenk RJ, Hopman WPM, Hoffmann AL, van Lin ENJT, Kaanders JHAM. Differences in radiation dosimetry and anorectal function testing imply that anorectal symptoms may arise from different anatomic substrates. Int J Radiat Oncol Biol Phys. 2012;82:145\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ijrobp.2009.08.050","volume":"78","author":"EK Yeoh","year":"2010","unstructured":"Yeoh EK, Bartholomeusz DL, Holloway RH, Fraser RJ, Botten R, Di Matteo A, et al. Disturbed colonic motility contributes to anorectal symptoms and dysfunction after radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2010;78:773\u201380. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s10350-004-6712-0","volume":"46","author":"RS Kushwaha","year":"2003","unstructured":"Kushwaha RS, Hayne D, Vaizey CJ, Wrightham E, Payne H, Boulos PB. Physiologic changes of the anorectum after pelvic radiotherapy for the treatment of prostate and bladder cancer. Dis Colon Rectum. 2003;46:1182\u20138. https:\/\/doi.org\/10.1007\/s10350-004-6712-0.","journal-title":"Dis Colon Rectum"},{"key":"1078_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/s0360-3016(00)00487-9","volume":"47","author":"EE Yeoh","year":"2000","unstructured":"Yeoh EE, Botten R, Russo A, McGowan R, Fraser R, Roos D, et al. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys. 2000;47:915\u201324. https:\/\/doi.org\/10.1016\/s0360-3016(00)00487-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/gut.27.5.528","volume":"27","author":"JS Varma","year":"1986","unstructured":"Varma JS, Smith AN, Busuttil A. Function of the anal sphincters after chronic radiation injury. Gut. 1986;27:528\u201333. https:\/\/doi.org\/10.1136\/gut.27.5.528.","journal-title":"Gut"},{"key":"1078_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/gut.43.1.123","volume":"43","author":"EK Yeoh","year":"1998","unstructured":"Yeoh EK, Russo A, Botten R, Fraser R, Roos D, Penniment M, et al. Acute effects of therapeutic irradiation for prostatic carcinoma on anorectal function. Gut. 1998;43:123\u20137. https:\/\/doi.org\/10.1136\/gut.43.1.123.","journal-title":"Gut"},{"key":"1078_CR26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3109\/0284186X.2015.1010693","volume":"54","author":"A Loganathan","year":"2015","unstructured":"Loganathan A, Schloithe AC, Hutton J, Yeoh EK, Fraser R, Dinning PG, et al. Pudendal nerve injury in men with fecal incontinence after radiotherapy for prostate cancer. Acta Oncol. 2015;54:882\u20138. https:\/\/doi.org\/10.3109\/0284186X.2015.1010693.","journal-title":"Acta Oncol"},{"key":"1078_CR27","unstructured":"Rome IV Criteria, n.d. Rome Foundation. https:\/\/theromefoundation.org\/rome-iv\/rome-iv-criteria\/ (accessed 30 January 2024)."},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ijrobp.2010.01.033","volume":"79","author":"H Geinitz","year":"2011","unstructured":"Geinitz H, Thamm R, Keller M, Astner ST, Heinrich C, Scholz C, et al. Longitudinal study of intestinal symptoms and fecal continence in patients with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79:1373\u201380. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.01.033.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ijrobp.2011.06.1953","volume":"83","author":"C Fiorino","year":"2012","unstructured":"Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, et al. Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions. Int J Radiat Oncol Biol Phys. 2012;83:38\u201345. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.06.1953.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.radonc.2013.09.028","volume":"110","author":"G Fellin","year":"2014","unstructured":"Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, et al. Long-term rectal function after high-dose prostate cancer radiotherapy: results from a prospective cohort study. Radiother Oncol. 2014;110:272\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2013.09.028.","journal-title":"Radiother Oncol"},{"key":"1078_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijrobp.2006.10.011","volume":"67","author":"C Buron","year":"2007","unstructured":"Buron C, Le Vu B, Cosset J-M, Pommier P, Peiffert D, Delannes M, et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. Int J Radiat Oncol Biol Phys. 2007;67:812\u201322. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.10.011.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-4-36","volume":"4","author":"M Pinkawa","year":"2009","unstructured":"Pinkawa M, Piroth MD, Fischedick K, Nussen S, Klotz J, Holy R, et al. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer\u2014predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiat Oncol. 2009;4:36. https:\/\/doi.org\/10.1186\/1748-717X-4-36.","journal-title":"Radiat Oncol"},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ijrobp.2009.05.057","volume":"77","author":"RJ Reidunsdatter","year":"2010","unstructured":"Reidunsdatter RJ, Lund J-A, Fransson P, Widmark A, Foss\u00e5 SD, Kaasa S. Validation of the intestinal part of the prostate cancer questionnaire \u201cQUFW94\u201d: psychometric properties, responsiveness, and content validity. Int J Radiat Oncol Biol Phys. 2010;77:793\u2013804. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.05.057.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/DCR.0b013e318207f85f","volume":"54","author":"MN Lamb","year":"2011","unstructured":"Lamb MN, Trabinino L, Hackford A. Patients\u2019 perspectives on fecal incontinence after brachytherapy for localized prostate cancer. Dis Colon Rectum. 2011;54:615\u201321. https:\/\/doi.org\/10.1007\/DCR.0b013e318207f85f.","journal-title":"Dis Colon Rectum"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.radonc.2006.05.004","volume":"79","author":"H Geinitz","year":"2006","unstructured":"Geinitz H, Zimmermann FB, Thamm R, Erber C, M\u00fcller T, Keller M, et al. Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiother Oncol. 2006;79:341\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2006.05.004.","journal-title":"Radiother Oncol"},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/pros.24852","volume":"85","author":"Y Belkacemi","year":"2025","unstructured":"Belkacemi Y, Coraggio G, Debbi K, Sirmai L, Hollande C, Rambaud E, et al. Relationship between radiation therapy and fecal incontinence in patients treated for localized prostate cancer: results of the French ICONES study. Prostate. 2025;85:492\u2013501. https:\/\/doi.org\/10.1002\/pros.24852.","journal-title":"Prostate"},{"key":"1078_CR37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2023.04.032","volume":"117","author":"PM Petersen","year":"2023","unstructured":"Petersen PM, Cook AD, Sydes MR, Clarke N, Cross W, Kynaston H, et al. Salvage radiation therapy after radical prostatectomy: analysis of toxicity by dose-fractionation in the RADICALS-RT trial. Int J Radiat Oncol Biol Phys. 2023;117:624\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.032.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","volume":"98","author":"S Rodda","year":"2017","unstructured":"Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:286\u201395. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.01.008.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijrobp.2018.05.013","volume":"102","author":"A Cicchetti","year":"2018","unstructured":"Cicchetti A, Avuzzi B, Palorini F, Ballarini F, Stucchi C, Fellin G, et al. Predicting late fecal incontinence risk after radiation therapy for prostate cancer: new insights from external independent validation. Int J Radiat Oncol Biol Phys. 2018;102:127\u201336. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.013.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/pcan.2009.56","volume":"13","author":"K Odrazka","year":"2010","unstructured":"Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, Sefrova J, et al. Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:138\u201343. https:\/\/doi.org\/10.1038\/pcan.2009.56.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1078_CR41","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj, https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed online 25\/05\/23."},{"key":"1078_CR42","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/SLA.0b013e31824f1c21","volume":"255","author":"KJ Emmertsen","year":"2012","unstructured":"Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012;255:922\u20138. https:\/\/doi.org\/10.1097\/SLA.0b013e31824f1c21.","journal-title":"Ann Surg"},{"key":"1078_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/DCR.0000000000001583","volume":"63","author":"C Keane","year":"2020","unstructured":"Keane C, Fearnhead NS, Bordeianou LG, Christensen P, Basany EE, Laurberg S, et al. International consensus definition of low anterior resection syndrome. Dis Colon Rectum. 2020;63:274\u201384. https:\/\/doi.org\/10.1097\/DCR.0000000000001583.","journal-title":"Dis Colon Rectum"},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/codi.14790","volume":"22","author":"M van Heinsbergen","year":"2020","unstructured":"van Heinsbergen M, Van der Heijden JAG, Stassen LP, Melenhorst J, de Witte E, Belgers EH, et al. The low anterior resection syndrome in a reference population: prevalence and predictive factors in the Netherlands. Colorectal Dis. 2020;22:46\u201352. https:\/\/doi.org\/10.1111\/codi.14790.","journal-title":"Colorectal Dis"},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2017.07.044","volume":"99","author":"RC Wortel","year":"2017","unstructured":"Wortel RC, Heemsbergen WD, Smeenk RJ, Witte MG, Krol SDG, Pos FJ, et al. Local protocol variations for image-guided radiation therapy in the multicenter Dutch Hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. Int J Radiat Oncol Biol Phys. 2017;99:1243\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.07.044.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR46","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.euo.2021.07.005","volume":"4","author":"JN Staffurth","year":"2021","unstructured":"Staffurth JN, Haviland JS, Wilkins A, Syndikus I, Khoo V, Bloomfield D, et al. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK\/06\/016). Eur Urol Oncol. 2021;4:980\u201392. https:\/\/doi.org\/10.1016\/j.euo.2021.07.005.","journal-title":"Eur Urol Oncol"},{"key":"1078_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ijrobp.2007.04.001","volume":"69","author":"T Wahlgren","year":"2007","unstructured":"Wahlgren T, Nilsson S, Lennern\u00e4s B, Brandberg Y. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69:662\u201370. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.04.001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR48","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23:1308\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4.","journal-title":"Lancet Oncol"},{"key":"1078_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2006.03.034","volume":"66","author":"STH Peeters","year":"2006","unstructured":"Peeters STH, Hoogeman MS, Heemsbergen WD, Hart AAM, Koper PCM, Lebesque JV. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys. 2006;66:11\u201319. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.03.034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR50","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.ijrobp.2007.07.2354","volume":"70","author":"C Fiorino","year":"2008","unstructured":"Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1130\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.07.2354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR51","doi-asserted-by":"publisher","unstructured":"Rancati, T, Fiorino, C, Fellin, G, Vavassori, V, Cagna, E, Casanova Borca, CV, et al. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high-dose radiotherapy for prostate cancer. Radiother Oncol. 2011;100:124\u201330. https:\/\/doi.org\/10.1016\/j.radonc.2011.06.032","DOI":"10.1016\/j.radonc.2011.06.032"},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.ijrobp.2011.03.056","volume":"82","author":"G Defraene","year":"2012","unstructured":"Defraene G, Van den Bergh L, Al-Mamgani A, Haustermans K, Heemsbergen W, Van den Heuvel F, et al. The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:1233\u201342. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.03.056.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR53","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/jrr\/rru061","volume":"55","author":"H Yamazaki","year":"2014","unstructured":"Yamazaki H, Nakamura S, Nishimura T, Yoshida K, Yoshioka Y, Koizumi M, et al. Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res. 2014;55:1033\u201347. https:\/\/doi.org\/10.1093\/jrr\/rru061.","journal-title":"J Radiat Res"},{"key":"1078_CR54","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3109\/0284186X.2015.1063779","volume":"54","author":"M Thor","year":"2015","unstructured":"Thor M, Olsson CE, Oh JH, Petersen SE, Alsadius D, Bentzen L, et al. Relationships between dose to the gastrointestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. Acta Oncol. 2015;54:1326\u201334. https:\/\/doi.org\/10.3109\/0284186X.2015.1063779.","journal-title":"Acta Oncol"},{"key":"1078_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijrobp.2006.03.055","volume":"66","author":"WD Heemsbergen","year":"2006","unstructured":"Heemsbergen WD, Peeters STH, Koper PCM, Hoogeman MS, Lebesque JV. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys. 2006;66:3\u201310. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.03.055.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2009.09.004","volume":"93","author":"G Fellin","year":"2009","unstructured":"Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, et al. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol. 2009;93:197\u2013202. https:\/\/doi.org\/10.1016\/j.radonc.2009.09.004.","journal-title":"Radiother Oncol"},{"key":"1078_CR57","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1080\/0284186X.2017.1370130","volume":"56","author":"O Casares-Magaz","year":"2017","unstructured":"Casares-Magaz O, Muren LP, Moiseenko V, Petersen SE, Pettersson NJ, H\u00f8yer M, et al. Spatial rectal dose\/volume metrics predict patient-reported gastrointestinal symptoms after radiotherapy for prostate cancer. Acta Oncol. 2017;56:1507\u201313. https:\/\/doi.org\/10.1080\/0284186X.2017.1370130.","journal-title":"Acta Oncol"},{"key":"1078_CR58","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ijrobp.2013.01.036","volume":"86","author":"DA Hamstra","year":"2013","unstructured":"Hamstra DA, Conlon ASC, Daignault S, Dunn RL, Sandler HM, Hembroff AL, et al. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013;86:546\u201353. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.01.036.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR59","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1080\/0284186X.2019.1635267","volume":"58","author":"E Onjukka","year":"2019","unstructured":"Onjukka E, Fiorino C, Cicchetti A, Palorini F, Improta I, Gagliardi G, et al. Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. Acta Oncol. 2019;58:1757\u201364. https:\/\/doi.org\/10.1080\/0284186X.2019.1635267.","journal-title":"Acta Oncol"},{"key":"1078_CR60","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.radonc.2016.04.005","volume":"119","author":"W Schaake","year":"2016","unstructured":"Schaake W, van der Schaaf A, van Dijk LV, Bongaerts AHH, van den Bergh ACM, Langendijk JA. Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients. Radiother Oncol. 2016;119:381\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2016.04.005.","journal-title":"Radiother Oncol"},{"key":"1078_CR61","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.ijrobp.2012.03.065","volume":"84","author":"D Alsadius","year":"2012","unstructured":"Alsadius D, Hedelin M, Lundstedt D, Pettersson N, Wilder\u00e4ng U, Steineck G. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2012;84:e181\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.065.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00066-005-1313-y","volume":"181","author":"P Mavroidis","year":"2005","unstructured":"Mavroidis P, al-Abany M, Helgason AR, Agren Cronqvist A-K, Wers\u00e4ll P, Lind H, et al. Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients. Strahlenther Onkol. 2005;181:293\u2013306. https:\/\/doi.org\/10.1007\/s00066-005-1313-y.","journal-title":"Strahlenther Onkol"},{"key":"1078_CR63","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ijrobp.2004.07.706","volume":"61","author":"M al-Abany","year":"2005","unstructured":"al-Abany M, Helgason \u00c1R, \u00c5gren Cronqvist A-K, Lind B, Mavroidis P, Wers\u00e4ll P, et al. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum. Int J Radiat Oncol Biol Phys. 2005;61:1035\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.07.706.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1078_CR64","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3109\/0284186X.2013.865077","volume":"53","author":"L Sander","year":"2014","unstructured":"Sander L, Langkilde NC, Holmberg M, Carl J. MRI target delineation may reduce long-term toxicity after prostate radiotherapy. Acta Oncol. 2014;53:809\u201314. https:\/\/doi.org\/10.3109\/0284186X.2013.865077.","journal-title":"Acta Oncol"},{"key":"1078_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen","volume":"3","author":"LE Miller","year":"2020","unstructured":"Miller LE, Efstathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e208221. https:\/\/doi.org\/10.1001\/jamanetworkopen.","journal-title":"JAMA Netw Open"},{"key":"1078_CR66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.brachy.2016.10.008","volume":"16","author":"B Kragelj","year":"2017","unstructured":"Kragelj B, Zlatic J, Zaletel-Kragelj L. Avoidance of late rectal toxicity after high-dose-rate brachytherapy boost treatment for prostate cancer. Brachytherapy. 2017;16:193\u2013200. https:\/\/doi.org\/10.1016\/j.brachy.2016.10.008.","journal-title":"Brachytherapy"},{"key":"1078_CR67","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/codi.15517","volume":"23","author":"P Christensen","year":"2021","unstructured":"Christensen P, Baeten CIM, Esp\u00edn-Basany E, Martellucci J, Nugent KP, Zerbib F, et al. Management guidelines for low anterior resection syndrome\u2014the MANUEL project. Colorectal Dis. 2021;23:461\u201375. https:\/\/doi.org\/10.1111\/codi.15517.","journal-title":"Colorectal Dis"},{"key":"1078_CR68","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.14309\/ajg.0000000000003413","volume":"120","author":"JW Blackett","year":"2025","unstructured":"Blackett JW, Bharucha AE. Fecal incontinence in adults: new therapies. Am J Gastroenterol. 2025;120:2027\u201341. https:\/\/doi.org\/10.14309\/ajg.0000000000003413.","journal-title":"Am J Gastroenterol"},{"key":"1078_CR69","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/SLA.0000000000005995","volume":"279","author":"SG Popeskou","year":"2024","unstructured":"Popeskou SG, Roesel R, Faes S, Vanoni A, Galafassi J, di Tor Vajana AF, et al. Ondansetron for low anterior resection syndrome (LARS): a double-blind, placebo-controlled, crossover, randomized study. Ann Surg. 2024;279:196\u2013202. https:\/\/doi.org\/10.1097\/SLA.0000000000005995.","journal-title":"Ann Surg"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01078-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:09Z","timestamp":1790719209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01078-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01078-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Use of generative AI in scientific writing upon submission of the paper: no.","order":2,"name":"Ethics","label":"Use of generative AI","group":{"name":"EthicsHeading","label":"Ethics"}}]}}